An observational study in Transthyretin Amyloidosis With Cardiomyopathy, sponsored by Alnylam Pharmaceuticals. Recruiting at 29 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Alnylam Pharmaceuticals · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 22 studies in Amyloidosis by Alnylam Pharmaceuticals — 6 open to participants now, 7 under way, 4 of them phase 3. Amyloidosis · Alnylam Pharmaceuticals.
Among the 22 studies in Amyloidosis by Alnylam Pharmaceuticals, this one is one of 2 that started in 2026, is one of 5 observational ones, and was the 22nd registered.
290 studies on the registry are indexed under Amyloidosis; 92 are open to participants now.
Browse Amyloidosis studies →6 of the 22 studies in Amyloidosis by Alnylam Pharmaceuticals are open now, in 12 countries. Recruiting first, the newest first:
Alnylam Pharmaceuticals · Sites in United States, Argentina, Australia and 19 more countries
Ages 18–85
Alnylam Pharmaceuticals · Sites in United States, Argentina, Australia and 33 more countries
Ages 18–85
Alnylam Pharmaceuticals · Sites in United States, Brazil, Bulgaria and 9 more countries
Alnylam Pharmaceuticals · Sites in United States, France, Germany and 4 more countries
Women only
Alnylam Pharmaceuticals · Sites in United States, Argentina, Austria and 14 more countries
Ages 18+
By country, each count listing its studies:
Of the 70 Amyloidosis studies recruiting now, 43 (61%) set no upper age limit and 3 (4%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
22 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 2 started in 2026.
This study's planned enrollment of 2,000 is above the median of 190 across 83 observational studies indexed under Amyloidosis.
Median enrollment 96 across the 15 interventional studies, 67 across the 5 observational. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
Alnylam Pharmaceuticals is the lead sponsor of 84 studies on the registry; 18 are open to participants now.
Of its 18 completed or terminated interventional studies of FDA-regulated products, 15 (83%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 22 studies in Amyloidosis by Alnylam Pharmaceuticals, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to:
Each site will invite all eligible patients to participate. Patients will be followed for up to 5 years or until patient withdrawal of consent, loss to follow-up, death, or the end of the study, whichever comes first.
The study population will include adult patients with ATTR-CM who, at enrollment, are either initiating treatment with vutrisiran or are initiating treatment with another approved ATTR-CM therapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Patients with ATTR-CM.
New York Heart Association (NYHA) Class
The NYHA functional classification categorizes the severity of heart failure. Patients are classified in 1 of 4 categories based on their physical limitations, as follows: * Class I No limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation, or shortness of breath. * Class II Slight limitation of physical activity. Comfortable at rest. Ordinary physical activity results in fatigue, palpitation, shortness of breath or chest pain. * Class III Marked limitation of physical activity. Comfortable at rest. Less than ordinary activity causes fatigue, palpitation, shortness of breath or chest pain. * Class IV Symptoms of heart failure at rest. Any physical activity causes further discomfort.
Time frame: From time of ATTR-CM diagnosis up to 5 years
Outpatient Diuretic Intensification
The clinician-reported outcome of ODI, which measures any post-diagnosis initiation or increase in the dose of loop diuretics, may help identify patients with ATTR-CM who are at an increased risk for adverse outcomes. ODI, a marker to monitor disease progression and/or worsening heart failure, is associated with a higher risk of all-cause mortality, cardiovascular hospitalizations, and urgent heart failure visits. Clinicians monitor ODI to help manage patients with ATTR-CM.
Time frame: From time of enrollment for up to 5 years
Norfolk Quality of Life - Diabetic Neuropathy (QOL-DN) Total Score
Norfolk-QoL-DN: The Norfolk QOL-DN questionnaire is a standardized 35-item patient-reported outcomes measure that assesses 6 domains: physical function, large-fiber neuropathy, activities of daily living, symptoms, small-fiber neuropathy, and autonomic neuropathy. The total score ranges from -4 points (best possible quality of life) to 136 points (worst possible quality of life).
Time frame: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
Kansas City Cardiomyopathy Questionnaire (KCCQ)
The KCCQ is a 23-item self-administered questionnaire developed to independently measure the patient's perception of health status, which includes heart failure symptoms, impact on physical and social function, and how their heart failure impacts their quality of life within a 2-week recall period. The KCCQ quantifies 6 domains (symptoms, physical function, quality of life, social limitation, self-efficacy, and symptom stability) and 2 summary scores (clinical and overall summary \[OS\] scores).
Time frame: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
Patient Global Impressions - Change (PGI-C)
The PGI-C is a 7-point numerical rating scale where 1 indicates "very much improved" and 7 indicates "very much worse."
Time frame: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
Patient Global Impressions - Severity (PGI-S);
The PGI-S is a 7-point numerical rating scale where 1 indicates "very much improved" and 7 indicates "very much worse."
Time frame: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
Treatment Satisfaction Questionnaire for Medication version 9 (TSQM-9)
TSQM-9 is a 9-item general instrument that measures the major dimensions of satisfaction with a medication. The questionnaire consists of 3 domains: effectiveness, convenience and side effects. The scores of each domain range from 0 to 100 with higher scores representing higher satisfaction on that domain.
Time frame: From time of enrollment (if available) or ATTR-CM diagnosis up to 5 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2026 (actual). Primary completion is estimated for Oct 2030, 57 months after the start.
Of 52 observational studies under Amyloidosis, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 183. This study's planned 57 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.